Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Maria Amann

Christian Klein

Sandra Grau-Richards

Pablo Umana

Claudia Ferrara Koller

Christina Claus

Peter Bruenker

Viktor Levitski

Ekkehard Moessner

Pablo Umaña

Guy Georges

Stefan Seeber

Joerg Thomas Regula

Ralf Hosse

Sabine Imhof-Jung

Joerg Zielonka

Laurene Pousse

Petra Rueger

Harald Duerr

Friederike Hesse

Alexander Haas

Samuel Moser

Alexander Bujotzek

Wei Xu

Roland Staack

Johannes Sam

Thomas Kraft

Estelle Marrer-Berger

Dietrich Tuerck

Reto Flury

Mudita Pincha

Rosmarie Albrecht

Juergen Peter Bachl

Carina Cantrill

Janine Faigle

Viktor Levitsky

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for OX40

The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.

Bispecific 2+1 contorsbodies

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules targeting OX40 and FAP

The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecule for a costimulatory TNF receptor

The present invention relates to a new cell based assay for combined determination of antibody or ligand binding and function in the same vial.

Cell based assay for determining antibody or ligand binding and function

The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.

Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer

Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (TnC) and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety

The invention relates to antibody or antibody fragments thereof that bind to OX40, methods of producing these antibodies and fragments, and to methods of using the same.

Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules

Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

Growing community of inventors

Duebendorf, Switzerland

Maria Amann